Article

 

Induced IL-10 Splice Altering Approach to Antiviral Drug Discovery Public Deposited

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/articles/rv042v839

Descriptions

Attribute NameValues
Creator
Abstract
  • Ebola virus causes an acute hemorrhagic fever lethal in primates and rodents. The contribution of host immune factors to pathogenesis has yet to be determined and may reveal efficacious targets for potential treatment. In this study, we show that the interleukin (IL)-10 signaling pathway modulates Ebola pathogenesis. IL-10 [superscript - / -] mice and wild-type mice receiving antisense targeting IL-10 signaling via disrupting expression through aberrant splice altering were resistant to ebola virus infection. IL-10 [superscript - / -] mice exhibited reduced viral titers, pathology, and levels of IL-2, IL-6, keratinocyte-derived chemokine (KC), and macrophage inflammatory protein-1 α and increased interferon (IFN)-γ relative to infected wild-type mice. Furthermore, antibody depletion studies in IL-10 [superscript - / -] mice suggest a requirement for natural killer cells and IFN-γ for protection. Together, these data demonstrate that resistance to ebola infection is regulated by IL-10 and can be targeted in a prophylactic manner to protect against lethal hemorrhagic virus challenge.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Panchal, R. G., Mourich, D. V., Bradfute, S., Hauck, L. L., Warfield, K. L., Iversen, P. L., & Bavari, S. (2014). Induced il-10 splice altering approach to antiviral drug discovery. Nucleic Acid Therapeutics, 24(3), 179-185. doi:10.1089/nat.2013.0457
Journal Title
Journal Volume
  • 24
Journal Issue/Number
  • 3
Rights Statement
Funding Statement (additional comments about funding)
  • Support from Postgraduate Research Participation Program at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRID) administered by the Oak Ridge Institute for Science and Education and the U.S. Department of Energy and the U.S. Army Medical Research and Materiel Command (USAMRMC). This work was supported by multiple contracts to Sarepta Therapeutics, Inc. by the Joint Project Manager-Transformational Medical Technologies Initiative (HDTRA1-07-C-0010).
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Made available in DSpace on 2015-03-02T17:34:56Z (GMT). No. of bitstreams: 1 MourichDanMicrobiologyInducedIL-10Splice.pdf: 643162 bytes, checksum: d5ca94c77b6605508bb8107fc89a1855 (MD5) Previous issue date: 2014-05-16
  • description.provenance : Submitted by Erin Clark (erin.clark@oregonstate.edu) on 2015-03-02T17:34:41Z No. of bitstreams: 1 MourichDanMicrobiologyInducedIL-10Splice.pdf: 643162 bytes, checksum: d5ca94c77b6605508bb8107fc89a1855 (MD5)
  • description.provenance : Approved for entry into archive by Erin Clark(erin.clark@oregonstate.edu) on 2015-03-02T17:34:56Z (GMT) No. of bitstreams: 1 MourichDanMicrobiologyInducedIL-10Splice.pdf: 643162 bytes, checksum: d5ca94c77b6605508bb8107fc89a1855 (MD5)

Relationships

Parents:

This work has no parents.

Items